HOLON, Israel, November 21, 2016 /PRNewswire/ --
Compugen Ltd. (NASDAQ: CGEN, a leading predictive drug discovery
company, today announced that Dr. Anat
Cohen-Dayag, President and Chief Executive Officer of
Compugen, will present a corporate introduction and overview at the
28th Annual Piper Jaffray Healthcare Conference in New York on Tuesday,
November 29 at 2:30 p.m. ET.
The slide presentation will be available on the Company's website
at such time.
About Compugen
Compugen is a leading therapeutic discovery company utilizing
its broadly applicable predictive discovery infrastructure to
identify novel drug targets and develop first-in-class biologics.
The primary focus of the Company's current pipeline is on immune
checkpoint target candidates discovered by the Company, potentially
providing the basis for a next wave of therapeutics for cancer
immunotherapy. Compugen's business model is based on selectively
entering into collaborations for its novel target candidates and
drug product candidates at various stages of research and
development under revenue-sharing agreements. The Company is
headquartered in Israel, with
R&D facilities in Israel and
South San Francisco. At the US facilities, monoclonal antibody
therapeutic candidates are discovered and developed against the
Company's novel target candidates. For additional information,
please visit Compugen's corporate website at
http://www.cgen.com.
Company contact:
Tsipi Haitovsky
Global Media Liaison
Compugen Ltd.
Email: tsipih@cgen.com
Tel: +972-52-598-9892
SOURCE Compugen Ltd.